Where to Buy Epithalon: Clinics Sell It, Pharmacies Cannot

Where to buy epithalon is usually answered with a shortlist of shops, which skips the part that actually determines how the purchase goes. The more useful question is what kind of seller you are dealing with, because the channel decides what documentation arrives with the vial, what happens if the parcel is stopped, and whether anything is recoverable when the order goes wrong. Those three things vary enormously between channels. Price varies far less.

This compound has one feature that sets it apart from the other Russian peptides sold beside it, and it changes the shape of the comparison. Selank and Semax are bought almost entirely as research material by people who found them through nootropics forums. Epithalon is also sold face to face, by longevity and anti-ageing clinics, to an older and considerably more motivated buyer. That gives the channel list a row that looks clinical, sits in a building with a receptionist, and is still not a pharmacy. Working out what that row actually is turns out to be the most valuable thing on this page.

Be precise about the molecule first, because the listings routinely are not. Epithalon is a synthetic tetrapeptide: four residues, Ala-Glu-Asp-Gly, listed at PubChem CID 219042 with the formula C14H22N4O9 and a molecular weight of 390.35. It derives from Russian work on a pineal extract called epithalamin. FDA and PubChem spell it Epitalon and the sellers spell it Epithalon, so where to buy epitalon and where can i buy epithalon are the same query about the same substance. One supplier is linked on this page and we earn a commission if you buy through it, as our affiliate disclosure explains.

Start with the closed door, because a number of search results imply it is ajar. A pharmacy compounding under section 503A of the Federal Food, Drug and Cosmetic Act may work from a bulk drug substance only if one of three conditions holds: the substance complies with a United States Pharmacopeia or National Formulary monograph, or it is a component of an FDA-approved drug product, or it appears on FDA's 503A bulks list. The agency states that test on its bulk drug substances page, content current as of 14 May 2026.

Epitalon fails all three conditions. There is no USP or NF monograph. No FDA-approved drug product contains it, because none has ever been approved anywhere in the United States. And it appears on no part of the bulks list today.

The third one has a history that generates most of the bad information online, so here it is precisely. Epitalon was nominated for the bulks list, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was subsequently withdrawn. It now sits on no category list at all. A page telling you it is category 2 is describing a status that ended; a page telling you it is banned has invented a word the agency did not use. Nominated and withdrawn is the accurate phrase, and the practical consequence for a buyer is the same in either reading.

It is worth knowing that this outcome is not automatic for everything sold on the same shelf, which is what makes the comparison instructive rather than academic. Our write-up on the compounded prescription route that genuinely does exist for NAD+ covers a substance FDA placed in category 1, where the agency has said it does not intend to take action against compounders meeting stated conditions. Epithalon has no equivalent, and neither does the Russian peptide most often stocked next to it, which reached the same withdrawn status by the same route.

This is the row that does not exist for most research peptides, and the row where a buyer is most likely to misread what they are being offered. Longevity and anti-ageing clinics do market Epithalon. We are not going to name any, invent prices for them or describe a chain that may not exist, because the useful information here is structural rather than a directory listing.

What such a clinic is selling is a consultation, an assessment, a protocol and an administration service, wrapped around a substance it cannot obtain through the pharmacy system. Since no compounding pharmacy can lawfully supply Epitalon, a clinic offering it has sourced the material somewhere else. That sourcing step is invisible to you and is the single thing you would most want to see. The clinical setting supplies real value on the surrounding services and supplies none at all on the provenance of what is in the vial, and those two are easy to conflate when you are sitting in a treatment room.

So the questions to ask are narrow and answerable. Where did this material come from, and can I see the certificate of analysis for the specific batch you are using? Was it tested for endotoxin and sterility, since you intend to inject it? Who compounded or reconstituted it, and under what conditions? A clinic with good answers has done work you can verify. A clinic that treats those questions as impertinent has told you what you needed to know. Our piece on what a longevity clinic is actually selling when it lists a peptide on its menu works through the same interview on a different compound.

The cost side follows from the model. You are paying for professional time and premises, and the peptide itself is a small fraction of the bill. That is not a criticism, it is just a different product from a vial. It does mean that comparing a clinic price with a vial price is a category error, and anyone doing it in either direction is arguing with the wrong number.

Search where to buy epithalon peptide rather than a service, and you land in one of three channels that all ship the same physical thing: a lyophilised solid in a sealed vial. Everything downstream of that differs.

Domestic research suppliers. A United States warehouse lists a sealed vial, usually 10 mg, labelled for laboratory research and not for human consumption. Payment is by card, dispatch is same or next day, and the variable that genuinely separates one seller from another is the certificate of analysis. The listing we link is a 10 mg vial at $50.00 list, marked down from $69.99, or $25.00 with the code PEPTIDEDECK. That is $2.50 per milligram on the label figure. Buying 3, 5 or 10 vials takes 3 percent, 5 percent or 10 percent off list separately, and free shipping starts at $250. Whether the code and the tiers combine is not documented anywhere we can point at, so do not plan around it. Figures checked on the listing on 23 August 2026.

Overseas marketplaces. The same powder appears on bulk chemical marketplaces sold by the gram, often at a fraction of the domestic per-milligram cost, because the buyer those listings are built for is a laboratory raising a purchase order. What changes is everything after checkout. A parcel crossing the border meets customs, and FDA's personal importation guidance is explicit that an unapproved drug offered for import may be refused entry. A refused parcel is not a refund. Transit runs to weeks with nobody temperature controlling anything, and certificates in this channel typically arrive on request after payment, frequently for a batch other than the one shipped.

Private resellers. The third channel is individuals working through forums, group chats and messaging apps, usually buying in bulk from the second channel and repackaging into vials. Repackaging severs the link between the certificate and the container: whatever testing the original material received described a drum of powder, not the vial somebody filled afterwards. This is also where FDA's stated concern lands hardest. The agency's worry about Epitalon is immunogenicity arising from aggregation and peptide-related impurities, which is a handling and manufacturing problem, and unqualified repackaging is exactly the step that creates those conditions while generating no new documentation at all. Payment is by peer-to-peer transfer or cryptocurrency, both final by design.

The table sets the five channels against what you receive, what can go wrong and how cost behaves. Only the domestic vial price is a figure we have checked against a live listing. The clinic and marketplace entries are structural, because those channels either quote per patient or move constantly, and inventing a number for them would be worse than leaving the cell honest.

Read the third column as the deciding one. The spread between these channels on price is smaller than the spread on what is recoverable when an order fails, and the cheapest-looking channel is reliably the one where nothing is.

The supplier we link publishes a certificate for batch 15-05260628, tested by Kovera Labs, report KVR-2026-A36FF4, certified 23 May 2026. Purity reports at 99.312 percent against a stated specification of greater than 98 percent. Identity is confirmed. The endotoxin safety screen passes against a limit of 0.5 EU/mL or lower, and the microbial sterility screen reports no growth. Heavy metals are screened.

It also reports a net content of 9.64 mg in a vial labelled 10 mg. The specification is 10 mg plus or minus 10 percent, so the batch passes, but the vial is under its label by 3.6 percent. That moves the real cost on that batch from $2.50 per milligram to $2.59. We publish both figures because the second one is the one you actually pay, and because a seller that prints a number slightly against itself is telling you something useful about how it handles documents. The same vendor's Selank lot ran the other way, assaying 12.29 mg against a 10 mg label. Either direction is fine. Not measuring at all is the problem.

Now the half a vendor would not write. FDA's position, from its page on bulk drug substances that may present significant safety risks, is that compounded drugs containing epitalon may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, and that the agency has not identified safety-related information regarding epitalon for the proposed route of administration.

Put the two together and you can see exactly how far the paperwork reaches. Aggregation and impurities are manufacturing problems, and testing is the right instrument for them, so a batch assayed for purity, confirmed for identity, screened for endotoxin and showing no growth has addressed a real part of what the agency named. What no certificate can produce is human safety data, and the agency's second sentence is about precisely that. A clean result on this batch means this batch was well made. It says nothing about what the compound does in a person, and both are true at once.

On the evidence, the domestic research supplier with a published, lot-specific certificate wins the comparison, and it wins on one axis: the volume of checkable evidence attached to the particular vial arriving at your address. It does not win because it is a good substitute for a prescription, because there is no prescription to substitute for. It wins because it is the only channel where you can read the document before the money moves.

The clinic row deserves a fairer send-off than a simple loss, though. If what you want is supervision, a clinic supplies something a vial cannot, and for an older buyer that can matter more than a certificate does. What it does not supply, and cannot, is a regulated supply chain, because none exists for this compound. Buying the supervision while assuming the supply chain came with it is the specific mistake this page exists to prevent.

Everything else falls away on the same filter. Marketplace listings that supply a certificate for somebody else's batch, resellers who repackage, tidy-looking shops with a purity figure and no specification behind it. What survives is a vial of research material with paperwork you can check, which is a genuinely different object from a medicine and deserves to be described that way.